IL126655A - Oral pharmaceutical formulation containing ibandronate - Google Patents

Oral pharmaceutical formulation containing ibandronate

Info

Publication number
IL126655A
IL126655A IL12665597A IL12665597A IL126655A IL 126655 A IL126655 A IL 126655A IL 12665597 A IL12665597 A IL 12665597A IL 12665597 A IL12665597 A IL 12665597A IL 126655 A IL126655 A IL 126655A
Authority
IL
Israel
Prior art keywords
ibandronate
coating
active substance
tablet
film
Prior art date
Application number
IL12665597A
Other languages
English (en)
Other versions
IL126655A0 (en
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7791961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL126655(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of IL126655A0 publication Critical patent/IL126655A0/xx
Publication of IL126655A publication Critical patent/IL126655A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
IL12665597A 1996-04-20 1997-04-21 Oral pharmaceutical formulation containing ibandronate IL126655A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19615812A DE19615812A1 (de) 1996-04-20 1996-04-20 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
PCT/EP1997/001940 WO1997039755A1 (de) 1996-04-20 1997-04-21 Orale pharmazeutische zubereitung enthaltend ibandronat

Publications (2)

Publication Number Publication Date
IL126655A0 IL126655A0 (en) 1999-08-17
IL126655A true IL126655A (en) 2004-12-15

Family

ID=7791961

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16393097A IL163930A0 (en) 1996-04-20 1997-04-21 An oral pharmaceutical formulation containing ibandronate
IL12665597A IL126655A (en) 1996-04-20 1997-04-21 Oral pharmaceutical formulation containing ibandronate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL16393097A IL163930A0 (en) 1996-04-20 1997-04-21 An oral pharmaceutical formulation containing ibandronate

Country Status (26)

Country Link
US (2) US6143326A (es)
EP (2) EP1658852B1 (es)
JP (2) JP5037746B2 (es)
CN (1) CN101152160A (es)
AR (2) AR006652A1 (es)
AT (1) ATE404207T1 (es)
AU (1) AU722516B2 (es)
BR (1) BR9708785A (es)
CA (1) CA2251886C (es)
CO (1) CO4820394A1 (es)
CZ (1) CZ297341B6 (es)
DE (2) DE19615812A1 (es)
DK (1) DK0936913T4 (es)
ES (1) ES2313735T5 (es)
HU (1) HU228389B1 (es)
IL (2) IL163930A0 (es)
NO (1) NO319162B1 (es)
NZ (1) NZ332314A (es)
PA (1) PA8427301A1 (es)
PL (2) PL191363B1 (es)
PT (1) PT936913E (es)
RU (1) RU2193881C2 (es)
SI (1) SI0936913T2 (es)
TR (1) TR199802108T2 (es)
WO (1) WO1997039755A1 (es)
ZA (1) ZA973331B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
KR100400053B1 (ko) * 1997-06-11 2003-09-29 더 프록터 앤드 갬블 캄파니 향상된 상부 위장관 안전용 필름 피복 정제
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US7008640B2 (en) * 2000-07-17 2006-03-07 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
CA2444718A1 (en) * 2001-05-02 2002-11-14 Novartis Ag Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
PL371264A1 (en) * 2001-12-21 2005-06-13 The Procter & Gamble Company Method for the treatment of bone disorders
SI1476138T1 (sl) 2002-02-21 2012-07-31 Valeant Internat Barbados Srl Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
DK1880744T3 (en) * 2002-05-10 2015-02-09 Hoffmann La Roche Bisphosphonic acids for the treatment and prevention of osteoporosis
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
PT1790347E (pt) * 2002-12-20 2015-02-05 Hoffmann La Roche Formulação de ibandronato a dose elevada
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
JP2009530414A (ja) * 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
CN101495101B (zh) * 2006-07-25 2012-02-29 兴和株式会社 糖衣制剂及其制造方法
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2009075601A1 (fr) * 2007-12-12 2009-06-18 Alexander Valerievich Melnik Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats
EP2210596A1 (en) * 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
MX341726B (es) * 2010-08-31 2016-08-31 Toray Ind Inc * Agente de revestimiento para preparacion solida farmaceutica, formulacion de pelicula farmaceutica, y preparacion solida farmaceutica revestida.
WO2012171576A1 (en) * 2011-06-17 2012-12-20 Evonik Röhm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
RU2485957C1 (ru) * 2012-03-16 2013-06-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE965825C (de) 1949-10-30 1957-06-19 Walter Kloepfer Dipl Ing Dr In Zur Antennenebene senkrecht polarisierter Strahler
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5098717A (en) * 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (es) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3699110B2 (ja) * 1993-05-15 2005-09-28 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性物質としてジクロロメチレンジホスホン酸を含む、改良された生物利用性を有する錠剤
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5803321A (en) * 1996-11-12 1998-09-08 Randy Hangers, Lll Hanger with ganging element
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
DE59712959D1 (de) 2008-09-25
BR9708785A (pt) 1999-08-03
CZ336498A3 (cs) 2000-01-12
ZA973331B (en) 1998-10-19
ES2313735T3 (es) 2009-03-01
CO4820394A1 (es) 1999-07-28
AR054350A2 (es) 2007-06-20
ES2313735T5 (es) 2012-12-07
SI0936913T1 (sl) 2008-12-31
RU2193881C2 (ru) 2002-12-10
CA2251886C (en) 2008-06-17
HU228389B1 (en) 2013-03-28
EP1658852A1 (de) 2006-05-24
AU722516B2 (en) 2000-08-03
SI0936913T2 (sl) 2012-11-30
EP1658852B1 (de) 2016-11-09
EP0936913B2 (de) 2012-09-19
US20050089573A1 (en) 2005-04-28
DE19615812A1 (de) 1997-10-23
CA2251886A1 (en) 1997-10-30
ATE404207T1 (de) 2008-08-15
PL191910B1 (pl) 2006-07-31
DK0936913T4 (da) 2012-11-19
PL329347A1 (en) 1999-03-29
NO319162B1 (no) 2005-06-27
NO984881L (no) 1998-10-19
AR006652A1 (es) 1999-09-08
TR199802108T2 (xx) 1999-01-18
DK0936913T3 (da) 2008-10-20
US6143326A (en) 2000-11-07
AU2638297A (en) 1997-11-12
CZ297341B6 (cs) 2006-11-15
NO984881D0 (no) 1998-10-19
JP5037746B2 (ja) 2012-10-03
PT936913E (pt) 2008-09-25
CN101152160A (zh) 2008-04-02
WO1997039755A1 (de) 1997-10-30
HUP9903407A2 (hu) 2000-04-28
IL126655A0 (en) 1999-08-17
EP0936913A1 (de) 1999-08-25
JP2008285500A (ja) 2008-11-27
IL163930A0 (en) 2005-12-18
JP5557989B2 (ja) 2014-07-23
NZ332314A (en) 2000-03-27
HUP9903407A3 (en) 2000-11-28
PA8427301A1 (es) 2002-07-30
JP2000508673A (ja) 2000-07-11
PL191363B1 (pl) 2006-05-31
EP0936913B1 (de) 2008-08-13

Similar Documents

Publication Publication Date Title
CA2251886C (en) An oral pharmaceutical formulation containing ibandronate
RU2120798C1 (ru) Твердая фармацевтическая композиция для перорального введения
EP1753395B1 (en) Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
US20050181053A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
CN109310642B (zh) 美沙拉嗪的口服药物组合物
NZ532564A (en) Solid unit dosage forms for oral administration which minimise the impact of coating fractures especially for larger or heavier dosage forms
WO2023281089A2 (en) Pharmaceutical composition comprising naproxen and paracetamol
US6096342A (en) Dosage forms of risedronate
KR100482931B1 (ko) 이반드로네이트를함유하는경구용약제학적제제
EP4366707A2 (en) Pharmaceutical composition comprising naproxen and paracetamol
CN1222079A (zh) 含有伊波膦酸盐的口服药物制剂

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired